<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> of bone marrow in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To explore the role of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e>, we examined the frequency of apoptotic cells by the in situ end labeling method in bone marrow specimens from 37 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> [<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) 10 cases, RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) 27 cases including 12 cases with leukemic transformation], 12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 13 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, we investigated the relationship of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> to the immunohistochemical expression of bcl-2 and p53 in these cases, and the association of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, bcl-2, and p53 with the leukemic evolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by examining sequential bone marrow samples of the same patient from the time of initial diagnosis to the time of overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The percentage frequency of apoptotic cells was significantly greater in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (RA: 9.46 +/- 2.99%, m +/- SD; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>: 5 </plain></SENT>
<SENT sid="4" pm="."><plain>60 +/- 3.09) as compared with those in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (0.62 +/- 0 </plain></SENT>
<SENT sid="5" pm="."><plain>37), de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (0.28 +/- 0.11) and controls (1.00 +/- 0.59) </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, the cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> with leukemic transformation exhibited a lower frequency of apoptotic cells and a higher frequency of bcl-2- and p53-positive cells than those without transformation </plain></SENT>
<SENT sid="7" pm="."><plain>When the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> cases transformed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, the frequency of apoptotic cells was significantly reduced (2.96 +/- 1 </plain></SENT>
<SENT sid="8" pm="."><plain>54 --&gt; 0.62 +/- 0.37), while the frequencies of bcl-2-positive cells and p53-positive cells were greater (10.88 +/- 3.66 --&gt; 30.54 +/- 7 </plain></SENT>
<SENT sid="9" pm="."><plain>14, and 20.21 +/- 6.21 --&gt; 32.34 +/- 14.71, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, over a half of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cases showed few p53-positive cells </plain></SENT>
<SENT sid="11" pm="."><plain>These findings corroborate the earlier notion that <z:mpath ids='MPATH_3'>apoptosis</z:mpath> may play a substantial role in dysplastic and ineffective hematopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>It is also suggested that the suppression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> associated with enhanced bcl-2 expression and p53 accumulation increases the probability of developing <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and that oncogenetic development might be different between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>